
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39294236
72688
10.1038/s41598-024-72688-2
Article
Associations between end stage renal disease and HLA polymorphisms in the Guangxi Zhuang population
Pei Yongfeng 12
Li Haibin 2
Huang Chengxin 2
Qin Yinhong 2
Sun Xuyong sunxuyong@gxmu.edu.cn

2
1 https://ror.org/03dveyr97 grid.256607.0 0000 0004 1798 2653 School of Basic Medicine, Guangxi Medical University, Nanning, China
2 https://ror.org/051mn8706 grid.413431.0 Institute of Transplantation Medicine, The Second Affiliated Hospital of Guangxi Medical University. Guangxi Clinical Research Center for Organ Transplantation. Guangxi Key Laboratory of Organ Donation and Transplantation, Nanning, China
18 9 2024
18 9 2024
2024
14 2176516 2 2024
10 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
To investigate the genetic relationship between end stage renal disease (ESRD) and human leukocyte antigen (HLA) alleles in the Guangxi Zhuang population. We performed polymerase chain reaction reversed sequence-specific oligonucleotide (PCR-rSSO) in 325 patients with ESRD and genotyped the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci. The direct counting method was used to determine the frequencies of HLA alleles, and Arlequin software (version 3.5.2.2) was used for haplotypic frequency analyses to compare the included ESRD patients with 350 healthy donors from the Guangxi Zhuang population. In our study, 120 HLA alleles, 284 HLA-A-B-DRB1 haplotypes, and 332 HLA-A-C-B-DRB1-DQB1 haplotypes were detected. We found that only A*11:01-B*15:02-DRB1*12:02 had a positive association with ESRD (P = 0.001, Pc = 0.020, OR = 3.106, 95% CI = 1.497–6.446) after Bonferroni correction; thus, individuals with this haplotype may be susceptible to ESRD. A*11:01-B*15:02-DRB1*12:02 is a potentially valuable haplotype for evaluating the risk of ESRD in the Guangxi Zhuang population.

Keywords

End stage renal disease
Guangxi Zhuang population
HLA
Allele frequency
Haplotype
Subject terms

Immunology
Medical research
Nephrology
the National Natural Science Foundation of China81670596 issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The most variable region on the 6th chromosome in the human genome, the human leukocyte antigen (HLA), plays important roles in resistance to infection, susceptibility to autoimmune disease, tumor resistance, and immune responses to allografts following organ donation1,2. In December 2023, the IMGT/HLA Database (version 3.54) reported that 38,008 HLA alleles had been found3. Racial and geographic restrictions govern the distribution of alleles and haplotypes at the HLA locus, and the distinction between racial and geographic restrictions is also significantly more pronounced at the allelic level than at the serologic level4,5.

End stage renal disease (ESRD) is the most severe stage of chronic kidney disease (CKD) and has become a significant global health problem6. A total of 10.8% of Chinese people have CKD, and the prevalence of ESRD is increasing each year7. Because it increases survival and improves patient quality of life, renal transplantation is acknowledged as the most successful therapeutic approach for ESRD8,9. HLA is a significant determinant of some autoimmune diseases, and it has been connected to the development of ESRD, along with genetics, race, age, and sex10. The allocation of kidneys for transplantation and the outcomes of kidney transplantation depend greatly on HLA matching11. Because the HLA-DRB1 alleles directly activate the recipient’s T helper lymphocytes, they should be given more weight in HLA matching12. Numerous studies have been conducted on the association between ESRD and HLA alleles. Some HLA alleles may increase susceptibility to ESRD, whereas other HLA alleles may provide protection13,14, indicating that specific susceptibility-associations alleles or variants may exist in different countries or races. Therefore, more evidence on the global distribution of susceptibility-associated HLA alleles and haplotypes can be obtained when genetic association research on different populations is reported. However, the majority of previously reported studies used low-resolution HLA typing.

Guangxi is a multiethnic province in China, and Guangxi Zhuang is the largest ethnic group, with a population of approximately 16 million. However, no studies have analyzed the relationships between ESRD and HLA polymorphisms in the Guangxi Zhuang population via high-resolution HLA typing. As a result, our findings provide new information on disease-associated factors in the Chinese population.

Subjects and methods

Subjects

This was a retrospective, case‒control study. We investigated the medical records of 5160 ESRD patients who were awaiting renal transplants at the transplant center of the Second Affiliated Hospital of Guangxi Medical University from 2014 to 2022. All research was performed in accordance with relevant guidelines and regulations. The 325 ESRD patients included in our study ranged in age from 15 to 65 years and included 188 men and 137 women. The patients were required to be of the Zhuang ethnicity and to have complete HLA typing data from all five loci to meet the inclusion criteria. We used the HLA typing results of 350 healthy volunteers from the Guangxi Branch of the Chinese Marrow Donor Program (CMDP) as controls. The donors were living at the time of the study and unrelated to the included patients. They included 176 men and 174 women between 18 and 48 years old who were of the Zhuang ethnicity and native to Guangxi15.

Ethical considerations

The Second Affiliated Hospital of Guangxi Medical University approved our study, and we obtained consent to collect original data. Therefore, the Ethics Committee of the Second Affiliated Hospital of Guangxi Medical University approved this study, and the need for informed consent was waived for (approval number: 2022-KY (0765)).

DNA extraction

We collected 2–5 ml of peripheral blood from ESRD patients using an EDTA anticoagulated blood collection tube. According to the manufacturer’s instructions, genomic DNA was extracted using a QIAamp blood kit (Qiagen, Hilden, Germany). The optical density at 260/280 nm was 1.65–1.9, and the DNA concentration was adjusted to between 30 and 100 ng/µl.

HLA genotyping

Samples from ESRD patients were subjecting to typing of the HLA-A, -B, -C, -DRB1, and -DQB1 loci via the PCR-rSSO method with LIFECODES HLA-SSO eRES TYPING KITS (LIFECODES, Waukesha, WI, USA) according to the manufacturer’s instructions. The product signals (One Lambda, Canoga Park, CA, USA) were detected with a Luminex-IS200 flow cytometer (Luminex Corporation, Austin, TX, USA), and HLA Fusion 3.0 software was used to perform HLA genotyping. The HLA genotyping results for the controls were derived from a previous study using sequence-based typing (SBT)15. The genotyping results of the two groups could be combined for analysis, although we used two different approaches, and the high-resolution standard for HLA typing was the same10.

Statistical analysis

The direct counting method was used to calculate the allele frequencies (AFs) of HLA-A, -B, -C, -DRB1, and -DQB1. The Arlequin software package (version no. 3.5.2.2) was used to estimate haplotypic frequencies with the expectation maximization (EM) algorithm16. The difference in the frequency of haplotypes between ESRD patients and controls was analyzed using SPSS version 19.0. Odds ratios (ORs) and 95% confidence intervals (CIs) were also computed with SPSS (version 19.0) and were used to express the degree to which disease was associated with a specific allele or haplotype. Bonferroni-corrected probability values (pc) were determined by multiplying individual p values by the number of comparisons made at the allele and haplotype levels. Results were considered statistically significant for p < 0.05.

Results

Association of HLA class I alleles (HLA-A, HLA-B, and HLA-C) with ESRD

Twenty-one HLA-A alleles, 39 HLA-B alleles, and 19 HLA-C alleles were detected in the ESRD patients (Tables 1, 2 and 3). Before applying the Bonferroni correction, our analysis revealed that B*40:01 (P = 0.027) may act as a protective factor against ESRD. In contrast, A*11:01 (P = 0.031), B*15:02 (P = 0.007), B*13:02 (P = 0.031), C*08:01 (P = 0.012), and C*15:02 (P = 0.011) may be susceptibility markers for ESRD. We found that the significance of these associations was lost after applying the Bonferroni correction for the HLA-A, -B, and -C loci.Table 1 HLA-A allele frequency in patients with ESRD and controls.

	ESRD (2n = 650)	Control (2n = 700)	P	Pc	OR	95% CI	
NO.	AF (%)	NO.	AF (%)	
11:01	221	34.00	200	28.57	0.031	NS	1.288	1.023–1.622	
24:02	92	14.15	117	16.71	0.194	NS	0.822	0.611–1.105	
02:03	83	12.77	111	15.86	0.106	NS	0.777	0.571–1.056	
02:07	77	11.85	75	10.71	0.511	NS	1.120	0.799–1.570	
33:03	55	8.46	60	8.57	0.942	NS	0.986	0.673–1.445	
11:02	30	4.62	42	6.00	0.258	NS	0.758	0.469–1.227	
02:01	25	3.85	19	2.71	0.242	NS	1.434	0.782–2.629	
02:06	17	2.62	19	2.71	0.910	NS	0.963	0.496–1.868	
26:01	15	2.31	16	2.29	0.979	NS	1.010	0.495–2.059	
29:01	7	1.08	14	2.00	0.171	NS	0.533	0.214–1.330	
30:01	7	1.08	4	0.57	0.302	NS	1.894	0.552–6.501	
03:01	6	0.92	7	1.00	0.885	NS	0.922	0.308–2.759	
31:01	5	0.77	2	0.29	0.272	NS	2.705	0.523–13.993	
24:03	3	0.46	1	0.14	0.357	NS	3.241	0.336–31.237	
01:01	1	0.15	5	0.71	0.220	NS	0.214	0.025–1.838	
23:01	1	0.15	0	0					
24:01	1	0.15	0	0					
24:07	1	0.15	0	0					
68:01	1	0.15	0	0					
74:01	1	0.15	3	0.43	0.625	NS	0.358	0.037–3.450	
74:02	1	0.15	0	0					
AF: allele frequencies; NO.: Number of individuals; p value was calculated by Chi2test or Fisher’s exact test; Pc: p value after Bonferroni correction; OR: Odds ratios; CI: confidence intervals. NS: not significant. Significant associations are indicated in bold.

Table 2 HLA-B allele frequency in patients with ESRD and controls.

	ESRD (2n = 650)	Control (2n = 700)	P	Pc	OR	95% CI	
NO.	AF (%)	NO.	AF (%)	
46:01	109	16.77	98	14.00	0.158	NS	1.238	0.920–1.665	
15:02	94	14.46	68	9.71	0.007	NS	1.571	1.127–2.190	
13:01	68	10.46	77	11.00	0.750	NS	0.945	0.669–1.335	
58:01	58	8.92	81	11.57	0.110	NS	0.749	0.525–1.068	
40:01	48	7.38	76	10.86	0.027	NS	0.655	0.448–0.956	
38:02	45	6.92	62	8.86	0.189	NS	0.765	0.513–1.141	
55:02	42	6.46	47	6.71	0.852	NS	0.960	0.624–1.476	
51:01	34	5.23	30	4.29	0.414	NS	1.233	0.745–2.038	
39:01	13	2.00	7	1.00	0.129	NS	2.020	0.801–5.096	
13:02	12	1.85	4	0.57	0.031	NS	3.273	1.050-10.199	
27:04	11	1.69	8	1.14	0.392	NS	1.489	0.595–3.725	
40:02	11	1.69	12	1.71	0.975	NS	0.987	0.432–2.253	
56:01	11	1.69	13	1.86	0.819	NS	0.910	0.405–2.045	
15:25	9	1.38	14	2.00	0.383	NS	0.688	0.296-1.600	
07:05	8	1.23	15	2.14	0.196	NS	0.569	0.240–1.351	
15:12	8	1.23	11	1.57	0.595	NS	0.781	0.312–1.953	
54:01	7	1.08	9	1.29	0.723	NS	0.836	0.309–2.257	
15:01	6	0.92	3	0.43	0.327	NS	2.165	0.539–8.691	
48:01	6	0.92	4	0.57	0.535	NS	1.621	0.455–5.771	
48:03	6	0.92	11	1.57	0.286	NS	0.584	0.215–1.587	
51:02	6	0.92	1	0.14	0.061	NS	6.512	0.782–54.240	
38:01	5	0.77	7	1.00	0.652	NS	0.767	0.242–2.430	
52:01	5	0.77	5	0.71	1.000	NS	1.078	0.311–3.739	
35:01	3	0.46	6	0.86	0.509	NS	0.536	0.134–2.153	
35:05	3	0.46	2	0.29	0.676	NS	1.618	0.270–9.716	
40:03	3	0.46	1	0.14	0.357	NS	3.241	0.336–31.237	
40:06	3	0.46	0	0					
37:01	2	0.31	1	0.14	0.611	NS	2.157	0.195–23.849	
39:05	2	0.31	0	0					
39:15	2	0.31	1	0.14	0.611	NS	2.157	0.195–23.849	
56:04	2	0.31	6	0.86	0.290	NS	0.357	0.072–1.775	
08:01	1	0.15	1	0.14	1.000	NS	1.077	0.067–17.255	
15:07	1	0.15	0	0		NS			
15:18	1	0.15	2	0.29	1.000	NS	0.538	0.049–5.945	
27:06	1	0.15	0	0		NS			
39:09	1	0.15	1	0.14	1.000	NS	1.077	0.067–17.255	
44:03	1	0.15	3	0.43	0.625	NS	0.358	0.037–3.450	
55:04	1	0.15	0	0		NS			
67:01	1	0.15	1	0.14	1.000	NS	1.077	0.067–17.255	
AF: allele frequencies; NO.: Number of individuals; p value was calculated by Chi2test or Fisher’s exact test; Pc: p value after Bonferroni correction; OR: Odds ratios; CI: confidence intervals. NS: not significant. Significant associations are indicated in bold.

Table 3 HLA-C allele frequency in patients with ESRD and controls.

	ESRD (2n = 650)	Control (2n = 700)	P	Pc	OR	95% CI	
NO.	AF (%)	NO.	AF (%)	
01:02	138	21.23	129	18.43	0.197	NS	1.193	0.913–1.560	
08:01	107	16.46	82	11.71	0.012	NS	1.485	1.089–2.025	
03:04	99	15.23	110	15.71	0.806	NS	0.964	0.717–1.295	
07:02	95	14.62	117	16.71	0.290	NS	0.853	0.635–1.145	
03:02	59	9.08	83	11.86	0.096	NS	0.742	0.522–1.056	
14:02	27	4.15	27	3.86	0.781	NS	1.080	0.627–1.862	
04:03	24	3.69	30	4.29	0.578	NS	0.856	0.495–1.481	
12:03	24	3.69	34	4.86	0.292	NS	0.751	0.440–1.281	
03:03	19	2.92	26	3.71	0.418	NS	0.781	0.428–1.424	
12:02	14	2.15	15	2.14	0.989	NS	1.005	0.481–2.099	
15:02	14	2.15	4	0.57	0.011	NS	3.830	1.254–11.697	
06:02	9	1.38	9	1.29	0.874	NS	1.078	0.425–2.733	
04:01	7	1.08	8	1.14	0.908	NS	0.942	0.340–2.612	
15:05	7	1.08	15	2.14	0.122	NS	0.497	0.201–1.227	
04:06	2	0.31	0	0					
08:03	2	0.31	2	0.29	1.000	NS	1.077	0.151–7.669	
01:03	1	0.15	0	0		NS			
03:17	1	0.15	2	0.29	1.000	NS	0.538	0.049–5.945	
14:03	1	0.15	1	0.14	1.000	NS	1.077	0.067–17.255	
AF: allele frequencies; NO.: Number of individuals; p value was calculated by Chi2test or Fisher’s exact test; Pc: p value after Bonferroni correction; OR: Odds ratios; CI: confidence intervals. NS: not significant. Significant associations are indicated in bold.

Association of HLA class II alleles (HLA-DRB1 and HLA-DQB1) with ESRD

Twenty-six HLA-DRB1 alleles and 15 HLA-DQB1 alleles were found in our study (Tables 4 and 5). Before applying the Bonferroni correction, we identified DRB1*14:54 (P = 0.005), DRB1*12:02 (P = 0.019), and DQB1*03:01 (P = 0.036) as potential susceptibility markers for ESRD. Concurrently, we found that DRB1*15:02 (P = 0.013) and DRB1*16:02 (P = 0.008) could serve as protective alleles against ESRD. After applying the Bonferroni correction, we found no association between HLA class II alleles (HLA-DRB1 and HLA-DQB1) and ESRD in the Guangxi Zhuang population.Table 4 HLA-DRB1 allele frequency in patients with ESRD and controls.

	ESRD (2n = 650)	Control (2n = 700)	P	Pc	OR	95% CI	
NO.	AF (%)	NO.	AF (%)	
15:01	109	16.77	102	14.57	0.267	NS	1.181	0.880–1.585	
14:54	102	15.69	74	10.57	0.005	NS	1.575	1.143–2.169	
16:02	70	10.77	110	15.71	0.008	NS	0.647	0.470–0.892	
12:02	60	9.23	41	5.86	0.019	NS	1.635	1.082–2.469	
03:01	56	8.62	76	10.86	0.166	NS	0.774	0.538–1.113	
15:02	44	6.77	74	10.57	0.013	NS	0.614	0.416–0.907	
04:05	36	5.54	27	3.86	0.143	NS	1.461	0.877–2.436	
09:01	29	4.46	48	6.86	0.058	NS	0.634	0.395–1.019	
11:01	28	4.31	22	3.14	0.257	NS	1.387	0.785–2.450	
13:12	26	4.00	34	4.86	0.445	NS	0.816	0.484–1.376	
14:05	18	2.77	12	1.71	0.189	NS	1.633	0.780–3.417	
07:01	13	2.00	14	2.00	1.000	NS	1.000	0.466–2.144	
10:01	10	1.54	16	2.29	0.318	NS	0.668	0.301–1.483	
04:03	9	1.38	5	0.71	0.224	NS	1.952	0.651–5.854	
14:04	9	1.38	9	1.29	0.874	NS	1.078	0.425–2.733	
08:03	8	1.23	12	1.71	0.462	NS	0.714	0.290–1.759	
12:01	5	0.77	5	0.71	1.000	NS	1.078	0.311–3.739	
04:06	4	0.62	1	0.14	0.202	NS	4.328	0.483–38.825	
13:02	3	0.46	8	1.14	0.164	NS	0.401	0.106–1.518	
16:01	3	0.46	0	0		NS			
11:06	2	0.31	2	0.29	1.000	NS	1.077	0.151–7.669	
14:07	2	0.31	1	0.14	0.611	NS	2.157	0.195–23.849	
04:04	1	0.15	2	0.29	1.000	NS	0.538	0.049–5.945	
08:02	1	0.15	1	0.14	1.000	NS	1.077	0.067–17.255	
14:03	1	0.15	0	0					
15:07	1	0.15	0	0					
AF: allele frequencies; NO.: Number of individuals; p value was calculated by Chi2test or Fisher’s exact test; Pc: p value after Bonferroni correction; OR: Odds ratios; CI: confidence intervals. NS: not significant. Significant associations are indicated in bold.

Table 5 HLA-DQB1 allele frequency in patients with ESRD and controls.

	ESRD (2n = 650)	Control (2n = 700)	P	Pc	OR	95% CI	
NO.	AF (%)	NO.	AF (%)	
05:02	220	33.85	245	35.00	0.656	NS	0.950	0.759–1.190	
03:01	111	17.08	91	13.00	0.036	NS	1.378	1.021–1.861	
06:01	85	13.08	84	12.00	0.550	NS	1.103	0.799–1.523	
02:01	56	8.62	80	11.43	0.086	NS	0.731	0.510–1.047	
05:03	38	5.85	37	5.29	0.653	NS	1.113	0.698–1.773	
03:03	32	4.92	52	7.43	0.057	NS	0.645	0.410–1.016	
05:01	31	4.77	43	6.14	0.268	NS	0.765	0.476–1.230	
04:01	27	4.15	19	2.71	0.145	NS	1.553	0.855–2.822	
03:02	20	3.08	12	1.71	0.100	NS	1.820	0.883–3.753	
02:02	12	1.85	8	1.14	0.285	NS	1.627	0.661–4.006	
06:02	7	1.08	12	1.71	0.321	NS	0.624	0.244–1.595	
04:02	4	0.62	5	0.71	1.000	NS	0.861	0.230–3.219	
06:10	4	0.62	4	0.57	1.000	NS	1.077	0.268–4.326	
06:04	2	0.31	3	0.43	1.000	NS	0.717	0.119–4.305	
06:09	1	0.15	5	0.71	0.220	NS	0.214	0.025–1.838	
AF: allele frequencies; NO: Number of individuals; p value was calculated by Chi2test or Fisher’s exact test; Pc: p value after Bonferroni correction; OR: Odds ratios; CI: confidence intervals. NS: not significant. Significant associations are indicated in bold.

Three-locus haplotype frequency in patients with ESRD and controls

We identified 284 HLA-A-B-DRB1 haplotypes in patients with ESRD via statistical analysis. Table 6 displays the 20 most common three-locus haplotypes. The top 20 three-locus haplotypes account for 39.70% of all haplotypes, and twelve haplotypes with frequencies higher than 1% account for 32.67% of all haplotypes. The most prevalent haplotype among patients with ESRD and controls was A*33:03-B*58:01-DRB1*03:01 (ESRD, 6.12% vs. controls, 6.86%). After applying the Bonferroni correction, we found that only A*11:01-B*15:02-DRB1*12:02 was positively associated with ESRD (P = 0.001, Pc = 0.020, OR = 3.106, CI = 1.497–6.446), so this haplotype might be susceptible to ESRD.Table 6 20 most frequent three-locus haplotypes in patients with ESRD and controls.

Haplotype	Frequnecy(%)	P	Pc	OR	95% CI	
ESRD (2n = 650)	Control
(2n = 700)	
A*33:03-B*58:01-DRB1*03:01	6.12	6.86	0.601	NS	0.891	0.577–1.375	
A*11:01-B*15:02-DRB1*15:01	4.95	2.69	0.033	NS	1.856	1.041–3.308	
A*02:07-B*46:01-DRB1*14:54	4.58	3.14	0.160	NS	1.491	0.851–2.613	
A*11:01-B*15:02-DRB1*12:02	4.24	1.44	0.001	0.020	3.106	1.497–6.446	
A*11:01-B*13:01-DRB1*15:01	2.45	2.15	0.696	NS	1.152	0.565–2.350	
A*02:07-B*46:01-DRB1*09:01	1.81	2.11	0.697	NS	0.859	0.399–1.849	
A*11:01-B*46:01-DRB1*14:54	1.75	0.44	0.022	NS	3.999	1.111–14.401	
A*02:03-B*55:02-DRB1*16:02	1.50	2.20	0.410	NS	0.714	0.318-1.600	
A*11:01-B*38:02-DRB1*15:02	1.49	1.18	0.527	NS	1.352	0.530–3.446	
A*11:01-B*13:01-DRB1*16:02	1.41	1.59	0.777	NS	0.879	0.362–2.136	
A*02:03-B*38:02-DRB1*16:02	1.29	3.00	0.025	NS	0.403	0.177–0.916	
A*29:01-B*07:05-DRB1*10:01	1.08	2.00	0.171	NS	0.533	0.214–1.330	
A*11:01-B*51:01-DRB1*14:04	0.98	0					
A*11:01-B*58:01-DRB1*03:01	0.96	1.03	0.885	NS	0.922	0.308–2.759	
A*02:03-B*55:02-DRB1*15:01	0.93	0					
A*11:01-B*40:01-DRB1*16:02	0.87	0					
A*02:03-B*38:02-DRB1*15:02	0.86	0					
A*11:01-B*15:02-DRB1*04:05	0.83	0.60	0.745	NS	1.349	0.361–5.045	
A*02:03-B*13:01-DRB1*16:02	0.83	0					
A*24:02-B*55:02-DRB1*14:54	0.77	0					

Five-locus haplotype frequency in patients with ESRD and controls

We found 332 HLA-A-C-B-DRB1-DQB1 haplotypes in patients with ESRD via statistical analysis. Table 7 displays the 20 most common five-locus haplotypes. The top 20 five-locus haplotypes accounted for 36.64% of all haplotypes, and the twelve haplotypes with frequencies higher than 1% account for 30.28% of all haplotypes. The most prevalent haplotype was A*33:03-C*03:02-B*58:01-DRB1*03:01-DQB1*02:01 in both ESRD patients and controls (ESRD, 6.15% vs. controls, 6.86%). After applying the Bonferroni correction, we found no association between ESRD and the five-locus haplotype of HLA in the Guangxi Zhuang population.Table 7 20 most frequent five-locus haplotypes in patients with ESRD and controls.

Haplotype	Frequnecy (%)	P	Pc	OR	95% CI	
ESRD (2n = 650)	Control (2n = 700)	
A*33:03-C*03:02-B*58:01-DRB1*03:01-DQB1*02:01	6.15	6.86	0.601	NS	0.891	0.577–1.375	
A*11:01-C*08:01-B*15:02-DRB1*15:01-DQB1*06:01	4.38	3.10	0.257	NS	1.387	0.785–2.450	
A*02:07-C*01:02-B*46:01-DRB1*14:54-DQB1*05:02	4.31	3.19	0.257	NS	1.387	0.785–2.450	
A*11:01-C*08:01-B*15:02-DRB1*12:02-DQB1*03:01	3.97	1.50	0.003	NS	2.875	1.375–6.010	
A*11:01-C*03:04-B*13:01-DRB1*16:02-DQB1*05:02	1.75	1.68	0.975	NS	0.987	0.432–2.253	
A*11:01-C*01:02-B*46:01-DRB1*14:54-DQB1*05:02	1.71	0.87	0.169	NS	1.991	0.732–5.415	
A*02:03-C*07:02-B*38:02-DRB1*16:02-DQB1*05:02	1.62	2.81	0.153	NS	0.585	0.278–1.231	
A*11:01-C*03:04-B*13:01-DRB1*15:01-DQB1*06:01	1.61	1.64	0.961	NS	0.979	0.413–2.320	
A*02:07-C*01:02-B*46:01-DRB1*09:01-DQB1*03:03	1.59	2.00	0.521	NS	0.766	0.338–1.736	
A*11:01-C*07:02-B*38:02-DRB1*15:02-DQB1*05:01	1.08	0					
A*29:01-C*15:05-B*07:05-DRB1*10:01-DQB1*05:01	1.08	2.00	0.171	NS	0.533	0.214–1.330	
A*11:01-C*14:02-B*51:01-DRB1*14:04-DQB1*05:03	1.04	0					
A*11:01-C*01:02-B*46:01-DRB1*09:01-DQB1*03:03	0.95	0.56	0.535	NS	1.621	0.455–5.771	
A*02:03-C*01:02-B*46:01-DRB1*14:54-DQB1*05:02	0.85	0.45	0.327	NS	2.165	0.539–8.691	
A*11:01-C*03:02-B*58:01-DRB1*03:01-DQB1*02:01	0.80	1.43	0.248	NS	0.535	0.182–1.573	
A*02:03-C*04:03-B*55:02-DRB1*16:02-DQB1*05:02	0.77	1.29	0.349	NS	0.595	0.198–1.785	
A*11:01-C*14:02-B*51:01-DRB1*14:54-DQB1*05:02	0.77	0.43	0.493	NS	1.801	0.429–7.566	
A*30:01-C*06:02-B*13:02-DRB1*07:01-DQB1*02:02	0.77	0					
A*11:01-C*08:01-B*15:02-DRB1*15:01-DQB1*05:02	0.76	0					
A*02:03-C*03:04-B*13:01-DRB1*16:02-DQB1*05:02	0.70	0					
p value was calculated by Chi2 test or Fisher’s exact test; Pc: p value after Bonferroni correction; OR: Odds ratios; CI: confidence intervals. NS: not significant. Significant associations are indicated in bold.

Discussion

HLA allele and haplotype distributions are restricted geographically and racially45, and the HLA matching is important in determining transplantation success17,18. According to many studies, there is a strong correlation between HLA alleles and ESRD10,13,14. China’s largest ethnic population is the Zhuang population from Guangxi. We conducted a high-resolution analysis of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci in patients with ESRD to identify the HLA polymorphisms associated with susceptibility to ESRD in the Guangxi Zhuang population. Our findings might be helpful for future research on genetic predispositions ESRD related to the HLA region.

We identified 21 HLA-A alleles, 39 HLA-B alleles, 19 HLA-C alleles, 26 HLA-DRB1 alleles, and 15 HLA-DQB1 alleles in our study. ESRD patients shared 16 alleles with frequencies greater than 10% with the controls: A*11:01, A*24:02, A*02:03, A*02:07, B*46:01, B*13:01, C*01:02, C*08:01, C*03:04, C*07:02, DRB1*15:01, DRB1*14:54, DRB1*16:02, DQB1*05:02, DQB1*03:01, and DQB1*06:01. The identification of these 16 alleles implies that matching donors for patients who carry these HLA alleles should be relatively easy to find, making kidney transplant allocation convenient and yielding better results. However, some susceptibility-associated alleles should receive more attention because they are significantly more common in ESRD patients than in controls before Bonferroni correction, which makes it more difficult to match patients with kidney transplants14.

In some studies, HLA alleles and ESRD were found to be significantly correlated, but most of these studies used low-resolution HLA typing. HLA-B*07, DQA1*06, and DQB1*03 may be susceptibility-associated alleles for ESRD in Vietnamese populations, while HLA-B*27 and DQB1*02 may be protective alleles19. HLA-A*11, HLA-A*34, HLA-A*69, HLA-B*41, HLA-B*50, HLA-DRB1*10, and HLA-DRB1*14 may be susceptibility-associated alleles for ESRD in Romanian populations, while HLA-DRB1*07, HLA-DRB1*08, and HLA-DRB1*13 may be protective alleles20. HLA-A*24 and HLA-B*35 may be protective alleles against ESRD in Indonesian populations21. HLA-B*50 may be a susceptibility-associated allele for ESRD in Pakistan, whereas HLA-B*40, DRB1*13, and DRB1*12 may be protective alleles22. HLA-DRB1*04 and DRB1*11 may be susceptibility-associated alleles for ESRD in the Henan Han population of China, whereas HLA-B*62 and DRB1*15 may be protective alleles23. HLA-B8 may be a susceptibility-associated allele for ESRD in Kuwaiti populations, and HLA-A*28 and HLA-DR*11 may be protective alleles24. HLA-A*02, -B*48, -B*52, and -B*55 were positively associated with ESRD in the Hunan Han population of China, whereas HLA-B*60 was negatively associated with ESRD25. HLA-A*24, B*54, B*55, B*60, and DRB1*04 may be susceptibility-associated alleles for ESRD in the Cantonese population in China26. HLA-B*15 and B*18 may be susceptibility-associated alleles for ESRD in Saudi Arabian populations, whereas HLA-A*26, B*39, and B*50 may be protective alleles27. DRB1*03 and DRB1*11 are markers for susceptibility to ESRD in Taiwanese populations, and HLA-DR8 might act as a protective factor28. HLA-DR17 is associated with ESRD due to MPGN in White and Black Americans29. HLA-A*11:01, A*31:01, B*15:01, B*55:02, B*39:05, DRB1*03:01, DRB1*04:03, DRB1*04:04, DRB1*04:05, DRB1*11:01, and DRB1*12:02 were found to be susceptibility-associated alleles in the Jiangsu Han population of China. In contrast, DRB1*15:01 was a protective allele10.

Some studies also reported no associations between specific HLA alleles and ESRD. One meta-analysis revealed no significant associations between the HLA-B*50, HLA-DQA1*3, B*40, DRB1*12, DRB1*13, and DQA1*6 alleles and ESRD30. HLA-B*51 was found to have no significant relationship with ESRD patients in Turkey31. The HLA and ESRD data presented above are contradictory to and inconsistent with those of our study. Vietnamese and Taiwanese individuals have different susceptibility-associated alleles but similar backgrounds, which may be related to differences in HLA polymorphisms across regions and races; more research on this topic is needed19,21,28.

According to one publication, HLA-C mismatch has a significant adverse effect on the outcomes of bone marrow transplants using unrelated donors32. Although no HLA-C alleles were associated with susceptibility to ESRD in the Guangxi Zhuang population in our study, further research should be conducted to determine whether the effect of HLA-C mismatch on survival in ESRD patients also has a significant negative clinical impact and may lead to poor prognoses. Haplotype polymorphisms are a component of HLA polymorphisms. The HLA haplotype and linkage disequilibrium are frequently used to search for donors and to elucidate the characteristics of the population being studied10,33. According to the findings of our study, the frequencies of most haplotypes did not differ significantly between ESRD patients and controls after Bonferroni correction, suggesting that should be relatively easy to find a donor to match a patient with those haplotypes23. A*11:01-B*15:02-DRB1*12:02 emerged as susceptibility-associated haplotypes for ESRD and showed strong and significant associations with disease. Donor selection on the basis of HLA haplotype mismatches was more critical than the number or type of HLA mismatches34. Specific HLA haplotypes may lead to an immune response to antigens, contributing to ESRD development10. For the long-term survival of renal transplantation patients, avoiding susceptibility-associated alleles and haplotypes in matched consanguineous donors is crucial35.

In our study, only A*11:01-B*15:02-DRB1*12:02 was positively associated with ESRD in the Guangxi Zhuang population after Bonferroni correction; thus, this haplotype may be associated with susceptibility to ESRD. We also found that the A*11:01-B*15:02-DRB1*12:02 haplotype is significant, while the single allele of these HLA alleles is not significant; linkage disequilibrium may lead to the above result. Our findings differ significantly from those reported for some populations, a typical outcome in genetic association studies. A few potential causes are differences in HLA allele distribution across geographical regions4,5, differences in pathogenic mechanisms and environmental triggers13, referral bias, the use of small populations with nonrepresentative sizes13,36, the use of different methods for HLA typing24, and differences in HLA allomorphs37. The previously common theories of linkage disequilibrium, receptor theory, and tumor immune escape mechanisms38 can only partially account for the relationship between HLA alleles and ESRD patients and do not fully elucidate the mechanisms involved; thus, further exploration is needed.

Our investigation was conducted without taking into account primary renal disease resulting in ESRD, as in some described studies21,25,27, which is one limitation of our study. The other main limitations of this study were the small number of HLA loci and the small population of patients used; thus, further research with larger patient samples, more HLA loci, and every condition that can cause ESRD is needed. Our findings may increase the success rate of kidney transplantation, provide information on disease-associated factors in the Chinese population, and lead to future research on ESRD susceptibility, especially in the Guangxi Zhuang population. Further research should be performed to validate the findings of our study.

Conclusions

This is the first report of a high-resolution analysis of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci in patients with ESRD to identify the HLA polymorphisms associated with susceptibility to ESRD in the Guangxi Zhuang population. We found that only A*11:01-B*15:02-DRB1*12:02 had a positive association with ESRD in the Guangxi Zhuang population after Bonferroni correction (P = 0.001, Pc=0.020, OR = 3.106, 95% CI = 1.497–6.446), so this haplotype may be associated with susceptibility to ESRD. Our findings will increase the success rate of kidney transplantation, provide information on disease-associated factors in the Chinese population, and lead to future research on ESRD susceptibility, especially in the Guangxi Zhuang population.

Acknowledgements

The authors thank all the participants in the study.

Author contributions

H.C.X. performed the experiments. Q.Y.H. analyzed the data. P.Y.F. and L.H.B. wrote the paper. S.X.Y. revised the paper. All authors have read and approved the final manuscript.

Funding

This project was sponsored by the grants from the National Natural Science Foundation of China (No. 81670596).

Data availability

The data presented in this study are available on request from the corresponding author.

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yongfeng Pei and Haibin Li contributed equally to this work.
==== Refs
References

1. Zhong C Cozen W Bolanos R Song J Wang S. S The role of HLA variation in lymphoma aetiology and survival J. Intern. Med. 2019 286 2 154 180 10.1111/joim.12911 31155783
Zhong, C., Cozen, W., Bolanos, R.,  Song, J. & Wang, S. S. The role of HLA variation in lymphoma aetiology and survival. J. Intern. Med. 286(2), 154–180 (2019).31155783
2. Kamiza AB Kamiza S Mathew CG HLA-DRB1 alleles and cervical cancer: A meta-analysis of 36 case-control studies Cancer Epidemiol. 2020 67 101748 10.1016/j.canep.2020.101748 32562888
Kamiza, A. B., Kamiza, S. & Mathew, C. G. HLA-DRB1 alleles and cervical cancer: A meta-analysis of 36 case-control studies. Cancer Epidemiol. 67, 101748 (2020).32562888
3. Barker DJ The IPD-IMGT/HLA database Nucleic Acids Res. 2023 51 D1 D1053 D1060 10.1093/nar/gkac1011 36350643
Barker, D. J. et al. The IPD-IMGT/HLA database. Nucleic Acids Res. 51(D1), D1053–D1060 (2023).36350643
4. Zou J Shen G Qiang W Zhu YY Li WX Study on the polymorphisms of HLA-ABCDQB1DRB1 alleles and haplotypes in Hubei Han population of China Int. J. Immunogenet. 2021 48 1 8 15 10.1111/iji.12516 32996280
Zou, J., Shen, G., Qiang, W., Zhu, Y. Y. & Li, W. X. Study on the polymorphisms of HLA-ABCDQB1DRB1 alleles and haplotypes in Hubei Han population of China. Int. J. Immunogenet. 48(1), 8–15 (2021).32996280
5. Baek IC Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1, and -DPB1 by next generation sequencing-based typing in Koreans in South Korea PLoS ONE 2021 16 6 e0253619 10.1371/journal.pone.0253619 34153078
Baek, I. C. et al. Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1, and -DPB1 by next generation sequencing-based typing in Koreans in South Korea. PLoS ONE 16(6), e0253619 (2021).34153078
6. Holley JL Advance care planning in CKD/ESRD: An evolving process Clin. J. Am. Soc. Nephrol. 2012 7 6 1033 1038 10.2215/CJN.00580112 22461536
Holley, J. L. Advance care planning in CKD/ESRD: An evolving process. Clin. J. Am. Soc. Nephrol. 7(6), 1033–1038 (2012).22461536
7. Chen F Wang M Jiang Y Prevalence of chronic kidney disease and metabolic related indicators in Mianzhu, Sichuan, China Front. Public Health 2024 11 1252110 10.3389/fpubh.2023.1252110 38298256
Chen, F., Wang, M. & Jiang, Y. Prevalence of chronic kidney disease and metabolic related indicators in Mianzhu, Sichuan, China. Front. Public Health 11, 1252110 (2024).38298256
8. Vareldzis R Naljayan M Reisin E The incidence and pathophysiology of the obesity paradox: Should peritoneal dialysis and kidney transplant be offered to patients with obesity and end stage renal disease? Curr. Hypertens. Rep. 2018 20 10 84 10.1007/s11906-018-0882-y 30051236
Vareldzis, R., Naljayan, M. & Reisin, E. The incidence and pathophysiology of the obesity paradox: Should peritoneal dialysis and kidney transplant be offered to patients with obesity and end stage renal disease?. Curr. Hypertens. Rep. 20(10), 84 (2018).30051236
9. Tepel M Pretransplant characteristics of kidney transplant recipients that predict posttransplant outcome Front. Immunol. 2022 13 945288 10.3389/fimmu.2022.945288 35958571
Tepel, M. et al. Pretransplant characteristics of kidney transplant recipients that predict posttransplant outcome. Front. Immunol. 13, 945288 (2022).35958571
10. Pan Q A single center study of protective and susceptible HLA alleles and haplotypes with end stage renal disease in China Hum. Immunol. 2019 80 11 943 947 10.1016/j.humimm.2019.09.001 31521393
Pan, Q. et al. A single center study of protective and susceptible HLA alleles and haplotypes with end stage renal disease in China. Hum. Immunol. 80(11), 943–947 (2019).31521393
11. Fejzić E HLA genotyping in patients with end stage renal disease waiting for cadaveric renal transplantation in Federation of Bosnia and Herzegovina Open Access Maced. J. Med. Sci. 2017 5 1 1 5 10.3889/oamjms.2017.015 28293306
Fejzić, E. et al. HLA genotyping in patients with end stage renal disease waiting for cadaveric renal transplantation in Federation of Bosnia and Herzegovina. Open Access Maced. J. Med. Sci. 5(1), 1–5 (2017).28293306
12. Kosmoliaptsis V Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation Kidney Int. 2014 86 5 1039 1048 10.1038/ki.2014.106 24717292
Kosmoliaptsis, V. et al. Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. Kidney Int. 86(5), 1039–1048 (2014).24717292
13. Shao LN Association between the polymorphism of HLA and ESRD in Dalian Han population located in North of China Immunol. Investig. 2018 47 2 212 219 10.1080/08820139.2017.1416397 29257902
Shao, L. N. et al. Association between the polymorphism of HLA and ESRD in Dalian Han population located in North of China. Immunol. Investig. 47(2), 212–219 (2018).29257902
14. Hieu HT Ha NT Song LH Nghi TH Association of human leukocyte antigen haplotypes with end stage renal disease in Vietnamese patients prior to first transplantation Transplant. Proc. 2019 51 8 2549 2554 10.1016/j.transproceed.2019.03.067 31473007
Hieu, H. T., Ha, N. T., Song, L. H. & Nghi, T. H. Association of human leukocyte antigen haplotypes with end stage renal disease in Vietnamese patients prior to first transplantation. Transplant. Proc. 51(8), 2549–2554 (2019).31473007
15. Pei YF Yu M Huang HN Chen JR Li HC Polymorphism of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequency at high resolution in Guangxi Zhuang population Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 28 4 1397 1405 32798433
Pei, Y. F., Yu, M., Huang, H. N., Chen, J. R. & Li, H. C. Polymorphism of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequency at high resolution in Guangxi Zhuang population. Zhongguo Shi Yan Xue Ye Xue Za Zhi 28(4), 1397–1405 (2020) (Chinese).32798433
16. Excoffier L Lischer HE Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows Mol. Ecol. Resour. 2010 10 3 564 567 10.1111/j.1755-0998.2010.02847.x 21565059
Excoffier, L. & Lischer, H. E. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 10(3), 564–567 (2010).21565059
17. Kumru Sahin G Unterrainer C Süsal C Critical evaluation of a possible role of HLA epitope matching in kidney transplantation Transpl. Rev. (Orlando) 2020 34 2 100533 10.1016/j.trre.2020.100533
Kumru Sahin, G., Unterrainer, C. & Süsal, C. Critical evaluation of a possible role of HLA epitope matching in kidney transplantation. Transpl. Rev. (Orlando) 34(2), 100533 (2020).
18. Alelign T Kidney transplantation: The challenge of human leukocyte antigen and its therapeutic strategies J. Immunol. Res. 2018 2018 5986740 10.1155/2018/5986740 29693023
Alelign, T. et al. Kidney transplantation: The challenge of human leukocyte antigen and its therapeutic strategies. J. Immunol. Res. 2018, 5986740 (2018).29693023
19. Le Pham NM Ong TP Vuong NL Van Tran B Nguyen TTH HLA types and their association with end stage renal disease in Vietnamese patients: A cross-sectional study Medicine (Baltimore) 2022 101 48 e31856 10.1097/MD.0000000000031856 36482584
Le Pham, N. M., Ong, T. P., Vuong, N. L., Van Tran, B. & Nguyen, T. T. H. HLA types and their association with end stage renal disease in Vietnamese patients: A cross-sectional study. Medicine (Baltimore) 101(48), e31856 (2022).36482584
20. Iancu Loga LI Association between human leukocyte antigen and end stage renal disease in patients from Transylvania, Romania Int. J. Mol. Sci. 2023 24 17 13383 10.3390/ijms241713383 37686189
Iancu Loga, L. I. et al. Association between human leukocyte antigen and end stage renal disease in patients from Transylvania, Romania. Int. J. Mol. Sci. 24(17), 13383 (2023).37686189
21. Susianti H Evaluation of human leukocyte antigen class I and class II in end stage renal disease occurrence in Indonesian transplantation patients Int. J. Nephrol. 2021 2021 4219822 10.1155/2021/4219822 34671491
Susianti, H. et al. Evaluation of human leukocyte antigen class I and class II in end stage renal disease occurrence in Indonesian transplantation patients. Int. J. Nephrol. 2021, 4219822 (2021).34671491
22. Noureen N Revisiting the association between human leukocyte antigen and end stage renal disease PLoS ONE 2020 15 9 e0238878 10.1371/journal.pone.0238878 32915858
Noureen, N. et al. Revisiting the association between human leukocyte antigen and end stage renal disease. PLoS ONE 15(9), e0238878 (2020).32915858
23. Shang W Comparison of HLA-A, -B and -DRB1 loci polymorphism between kidney transplants of uremia patients and healthy individuals in Central China PLoS ONE 2016 11 10 e0165426 10.1371/journal.pone.0165426 27780235
Shang, W. et al. Comparison of HLA-A, -B and -DRB1 loci polymorphism between kidney transplants of uremia patients and healthy individuals in Central China. PLoS ONE 11(10), e0165426 (2016).27780235
24. Mosaad YM Association between human leukocyte antigens (HLA-A, -B, and -DR) and end stage renal disease in Kuwaiti patients awaiting transplantation Ren. Fail. 2014 36 8 1317 1321 10.3109/0886022X.2014.937672 25010329
Mosaad, Y. M. et al. Association between human leukocyte antigens (HLA-A, -B, and -DR) and end stage renal disease in Kuwaiti patients awaiting transplantation. Ren. Fail. 36(8), 1317–1321 (2014).25010329
25. Long L Sun Q Association of end stage renal disease with HLA phenotypes and panel reactive antibodies in patients awaiting renal transplantation in Hunan Province J. Clin. Lab. Anal. 2022 36 3 e24251 10.1002/jcla.24251 35083784
Long, L. & Sun, Q. Association of end stage renal disease with HLA phenotypes and panel reactive antibodies in patients awaiting renal transplantation in Hunan Province. J. Clin. Lab. Anal. 36(3), e24251 (2022).35083784
26. Cao Q HLA polymorphism and susceptibility to end stage renal disease in Cantonese patients awaiting kidney transplantation PLoS ONE 2014 9 6 e90869 10.1371/journal.pone.0090869 24603486
Cao, Q. et al. HLA polymorphism and susceptibility to end stage renal disease in Cantonese patients awaiting kidney transplantation. PLoS ONE 9(6), e90869 (2014).24603486
27. Hamdi NM Al-Hababi FH Eid AE Correction: HLA Class I and Class II Associations with ESRD in Saudi Arabian Population PLoS ONE 2017 12 12 e0190127 10.1371/journal.pone.0190127 29253021
Hamdi, N. M., Al-Hababi, F. H. & Eid, A. E. Correction: HLA Class I and Class II Associations with ESRD in Saudi Arabian Population. PLoS ONE 12(12), e0190127 (2017).29253021
28. Dai CS Association between human leucocyte antigen subtypes and risk of end stage renal disease in Taiwanese: A retrospective study BMC Nephrol. 2015 16 177 10.1186/s12882-015-0165-7 26518904
Dai, C. S. et al. Association between human leucocyte antigen subtypes and risk of end stage renal disease in Taiwanese: A retrospective study. BMC Nephrol. 16, 177 (2015).26518904
29. Afolabi H The association of class I and II human leukocyte antigen serotypes with end stage kidney disease due to membranoproliferative glomerulonephritis and dense deposit disease Am. J. Kidney Dis. 2024 83 1 79 89 10.1053/j.ajkd.2023.06.005 37739026
Afolabi, H. et al. The association of class I and II human leukocyte antigen serotypes with end stage kidney disease due to membranoproliferative glomerulonephritis and dense deposit disease. Am. J. Kidney Dis. 83(1), 79–89 (2024).37739026
30. Noureen N Zaidi N Association between human leukocyte antigen (HLA) and end stage renal disease (ESRD): A meta-analysis Peer J. 2023 11 e14792 10.7717/peerj.14792 36815988
Noureen, N. & Zaidi, N. Association between human leukocyte antigen (HLA) and end stage renal disease (ESRD): A meta-analysis. Peer J. 11, e14792 (2023).36815988
31. Kavuzlu M Zengel B Baştürk B HLA-B*51 frequency in transplant patients and donors Exp. Clin. Transpl. 2024 22 Suppl 1 265 269
Kavuzlu, M., Zengel, B. & Baştürk, B. HLA-B*51 frequency in transplant patients and donors. Exp. Clin. Transpl. 22(Suppl 1), 265–269 (2024).
32. Woolfrey A HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation Biol. Blood Marrow Transpl. 2011 17 6 885 892 10.1016/j.bbmt.2010.09.012
Woolfrey, A. et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transpl. 17(6), 885–892 (2011).
33. Qi J Relationship between high-resolution HLA-A,-B,-DRB1 alleles and haplotype polymorphisms with myeloid leukemia of Han People in North China Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 26 1 32 41 29397815
Qi, J. et al. Relationship between high-resolution HLA-A,-B,-DRB1 alleles and haplotype polymorphisms with myeloid leukemia of Han People in North China. Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(1), 32–41 (2018) (Chinese).29397815
34. Brifkani Z The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation Transplant 2017 3 3 e133
Brifkani, Z. et al. The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation. Transplant 3(3), e133 (2017).
35. Miles CD Schaubel DE Liu D Port FK Rao PS The role of donor-recipient relationship in long-term outcomes of living donor renal transplantation Transplantation 2008 85 10 1483 1488 10.1097/TP.0b013e3181705a0f 18497690
Miles, C. D., Schaubel, D. E., Liu, D., Port, F. K. & Rao, P. S. The role of donor-recipient relationship in long-term outcomes of living donor renal transplantation. Transplantation 85(10), 1483–1488 (2008).18497690
36. El-Gezawy EM Human leukocyte antigens as a risk factor for the primary diseases leading to end stage renal disease in Egyptian patients Egypt. J. Immunol. 2011 18 2 13 21 23082466
El-Gezawy, E. M. et al. Human leukocyte antigens as a risk factor for the primary diseases leading to end stage renal disease in Egyptian patients. Egypt. J. Immunol. 18(2), 13–21 (2011).23082466
37. Robson KJ Ooi JD Holdsworth SR Rossjohn J Kitching AR HLA and kidney disease: From associations to mechanisms Nat. Rev. Nephrol. 2018 14 10 636 655 10.1038/s41581-018-0057-8 30206339
Robson, K. J., Ooi, J. D., Holdsworth, S. R., Rossjohn, J. & Kitching, A. R. HLA and kidney disease: From associations to mechanisms. Nat. Rev. Nephrol. 14(10), 636–655 (2018).30206339
38. Lee KW Yam JWP Mao X Dendritic cell vaccines: A shift from conventional approach to new generations Cells 2023 12 17 2147 10.3390/cells12172147 37681880
Lee, K. W., Yam, J. W. P. & Mao, X. Dendritic cell vaccines: A shift from conventional approach to new generations. Cells 12(17), 2147 (2023).37681880
